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Introduction
his section will discuss extinction of conditioned
fear and how it is mediated by a protein called the N-
methyl-D-aspartate (NMDA) receptor in the amygdala
and medial prefrontal cortex. This will be followed by a
review of the literature showing that a compound called
D-cycloserine, which facilitates the NMDA receptor,
speeding up extinction in animals and psychotherapy in
people. Much of this progress can be attributed to the
use of Pavlovian fear conditioning as a model system. In
this paradigm, an initially innocuous stimulus, the to-be
conditioned stimulus (eg, a light, tone, or distinctive
place) is paired with an innately aversive unconditioned
stimulus (eg, a footshock in rats, a blast of air to the
throat in humans) and the subject comes to exhibit a
conditioned fear response to the conditioned stimulus.
In rodents, fear is defined operationally as a cessation of
all bodily movements except those required for respira-
tion (freezing), an increase in the amplitude of an
acoustically elicited startle response (fear-potentiated
startle), an increase in blood pressure, changes in respi-
ration, emission of ultrasonic distress calls, avoidance of
the place where shock occurred, or several other possi-
ble measures, in the presence of the conditioned stimu-
lus. In humans fear is typically measured as a change in
skin conductance and increased startle when elicited in
the presence of the conditioned stimulus. Unlike
Pavlov’s dog, which salivated when it heard the
metronome, just as it did when it swallowed the dry food
powder, the fear response may or may not mimic the
unconditioned response to the aversive stimulus. For
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Based primarily on studies that employ Pavlovian fear
conditioning, extinction of conditioned fear has been
found to be mediated by N-methyl-D-aspartate
(NMDA) receptors in the amygdala and medial pre-
frontal cortex. This led to the discovery that an NMDA
partial agonist, D-cycloserine, could facilitate fear
extinction when given systemically or locally into the
amygdala. Because many forms of cognitive behavioral
therapy depend on fear extinction, this led to the suc-
cessful use of D-cycloserine as an adjunct to psy-
chotherapy in patients with so-called simple phobias
(fear of heights), social phobia, obsessive-compulsive
behavior, and panic disorder. Data in support of these
conclusions are reviewed, along with some of the pos-
sible limitations of D-cycloserine as an adjunct to psy-
chotherapy.    
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the conditioned fear response is just the opposite; they
freeze and hold very still. Hence, fear is really a hypo-
thetical construct that is used to describe the constella-
tion of behaviors that are seen following fear condition-
ing, and these may or may not mimic what happens in
the presence of the unconditioned stimulus.
Fear is a highly adaptive form of learning that prevents
us from returning to a place where we were harmed
(the alley where you were raped) or distraught (the air-
plane where we had a very bumpy flight) or contacting
something that was harmful (a hot burner on a stove).
Fear conditioning can be produced by a single training
trial, and fear memories can last a lifetime. Normally,
fear memories are suppressed by the process called fear
extinction or habituation when the situation signals that
these cues are no longer dangerous (eg, a soldier return-
ing from combat) or when they are experienced over
and over again in the absence of any negative conse-
quence (eg, multiple smooth airplane flights). However,
fear can become pathological if a person continues to
be afraid in situations where they no longer should be
afraid. For example, a soldier who is still afraid of a heli-
copter or the sound of a car backfiring long after he
returned from service is no longer adaptive; he has a
deficit in extinction or the ability to respond appropri-
ately to safety signals (eg, as seen in post-traumatic
stress disorder). 
Extinction—behavioral characteristics
As mentioned above, extinction of fear refers to the
reduction in the measured level of fear to a cue previ-
ously paired with an aversive event when that cue is pre-
sented repeatedly in the absence of the aversive event.
Actually, the term extinction is used in several different
ways in the literature. Extinction may refer to: (i) the
experimental procedure used to produce a decrement in
the fear response; (ii) the decremental effect of this pro-
cedure on the fear response, which can be measured
both at the time the cue is presented in the absence of
the aversive event and at a later time; or (iii) the hypoth-
esized associative or cellular process responsible for that
effect. As suggested elsewhere,
1 we will define the exper-
imental procedure as extinction training, the decrement
in the fear response measured during extinction training
as within-session extinction, and the decrement mea-
sured at some interval after extinction training as extinc-
tion retention. The term extinction will be reserved for
the process underlying the loss of the fear response.
Extinction is not the same as forgetting
Although some forgetting of the original conditioned
fear association may occur in extinction (see outstand-
ing review),
2 numerous studies show that extinction can-
not fully be explained by forgetting because it requires
exposure to the conditioned stimulus in the absence of
the aversive event as opposed to the simple passage of
time.
Extinction is generally cue-specific
Most studies show that fear extinction is cue-specific. For
example, if a tone is paired with a shock and a light is
paired with a shock, and then extinction training is only
given to the tone, fear of the light will be undiminished.
Generalization gradients of extinction are typically seen
where the magnitude of extinction is greatest to the cue
given during extinction training, and less so to cues along
some continuum, such as a series of different auditory
frequencies that received no extinction training.
3
Generalization of extinction is negligible across cues
drawn from different sensory modalities, or drawn from
a single modality but differing substantially in their phys-
ical characteristics. 
Extinction generally is not permanent
The decrement in conditioned fear responses during and
shortly after extinction training generally is not perma-
nent, as there are several instances in which extinguished
fear responses are observed to reappear. 
Reinstatement
This refers to the reappearance of a fear response fol-
lowing exposure to unsignaled presentations of the
unconditioned stimulus after the completion of extinction
training.
4 Unsignaled unconditioned stimulus presenta-
tions must occur within the context in which animals ulti-
mately are tested if a return of fear is to be observed.
5,6
Thus, reinstatement seems to depend on context condi-
tioning and is likely to involve summation of two fear-
inducing tendencies, each behaviorally subthreshold when
considered independently, but suprathreshold when com-
464
Translational research
PAGES_12_AG_1005_BA.qxd:DCNS#51  1/12/11  14:54  Page 464bined: weak conditioning to context and residual condi-
tioned fear to the extinguished stimulus (see ref 7).
Renewal
Renewal refers to a reappearance of extinguished fear
when animals are tested in a context different from the
one in which extinction training took place. For exam-
ple, when animals are first trained to fear a light in con-
text A, then receive extinction training to the light in
context B, and finally are tested for fear to the light in
either context A or context B, different outcomes are
obtained: animals tested in context B (the same context
where extinction training took place) exhibit little fear
to the light, whereas animals tested in context A exhibit
robust fear to the light.
6,8A similar postextinction return
of fear is observed when animals are tested in a third,
novel context C following acquisition in context A and
extinction in context B.
8,9Thus, rather than learning that
“now the cue is no longer paired with the shock,” the
animal learns that “now, in this place, the cue is no longer
paired with the shock.” 
Spontaneous recovery 
Spontaneous recovery refers to a reappearance of fear
with the passage of time following extinction training in
the absence of any further explicit training.
10
So, extinction is not a full erasure of the original fear
memory but instead an active form of learning that acts
to suppress or inhibit the original fear memory. This sec-
ond learning process is referred to as “inhibitory” learn-
ing, as opposed to the original “excitatory” learning that
occurred during pairings between the conditioned and the
unconditioned stimulus. These two types of learning work
at cross-purposes in terms of their tendency to stimulate
or oppose, respectively, fear output, eg, refs 11-13. In other
words, the conditioned stimulus emerges from extinction
training with two meanings: following acquisition, the con-
ditioned stimulus signals that an aversive event is coming,
and following extinction, the conditioned stimulus signals
that an aversive event will be withheld.
11
To account for recovery of fear following extinction, the
inhibitory learning that accrues in extinction may not be
expressed either because it is particularly “fragile” and
subject to disruption or because it is gated by context,
where “context” is defined broadly to include temporal
and interoceptive cues, as well as spatial ones.
11 That is,
following extinction, appropriate behavior (no fear) is
expressed within the temporal and spatial context of
extinction training, whereas acquisition-appropriate
behavior (fear) is expressed at other times and in other
places. 
Extinction may be “erased” under certain 
circumstances
Recently, however, new data have emerged in support
of a mechanism more consistent with an “unlearning”
account of extinction, in which plasticity underlying fear
memory is reversed through a process known as synap-
tic depotentiation. Depotentiation refers to a reversal of
long-term potentiation (ie, a return of potentiated
synapses to baseline synaptic efficacy) when low-fre-
quency stimulation is applied to afferent pathways
shortly following induction of long-term potentiation.
Evidence indicates that the biochemical and molecular
mechanisms of depotentiation are opposite to those of
long-term potentiation. For example, long-term potenti-
ation is associated with membrane insertion of non-
NMDA receptors.
14 Depotentiation, by contrast, is asso-
ciated with internalization of the same type of receptors
(see ref 15). 
Po-Wu Gean and colleagues demonstrated that depo-
tentiation occurs in the amygdala.
16,17 For example, depo-
tentiation-inducing low-frequency stimulation of the
amygdala in vivo 10 min after fear acquisition blocked
the expression of conditioned fear 24 h later, an effect
that could be interpreted as a mimicking of extinction.
16
These findings are intriguing, but puzzling, because they
would seem to offer no explanation of recovery of fear
following extinction through reinstatement, renewal, or
spontaneous recovery. Although “new learning” and
“unlearning” mechanisms of extinction are often pre-
sented as mutually exclusive possibilities, it has been
acknowledged that both may occur to some extent, eg,
ref 2. Interestingly, depotentiation is inducible more
readily at short intervals following induction of long-
term potentiation and does not seem to be inducible at
all at intervals greater than about 1 h (see ref 18). In
rodents, extinction studies typically do not use intervals
between acquisition and extinction training of less than
24 h, although biochemical processes of extinction were
reported to be different when extinction training was
conducted immediately following acquisition compared
with 1 h or 3 h after extinction training.
19
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shortly after conditioning might “erase” the original fear
memory, rats were fear conditioned and then given
extinction training either 10 min, 1 h, 24 h, or 3 days
later.
18 Consistent with an inhibitory learning mechanism
of extinction, rats extinguished 24 or 72 h following
acquisition exhibited moderate to strong reinstatement,
renewal, and spontaneous recovery. By contrast, and
consistent with an erasure mechanism, rats extinguished
10 min to 1 h after acquisition exhibited little or no rein-
statement, renewal, or spontaneous recovery. These data
support a model in which different neural mechanisms
are recruited depending on the temporal delay of fear
extinction. Based on these results, Dr Barbara
Rothbaum’s group at Emory has been testing whether a
full therapeutic dose of exposure therapy in the emer-
gency room will lead to stronger fear extinction in trau-
matized individuals compared with delayed extinction,
although the results are not yet fully in. 
Extinction training after memory recall may also
“erase” fear memories
Very similar results have been found when extinction
training was carried out 10 min to 1 h after fear memory
recall.
20 Rats were trained to associate a tone with a foot-
shock and then divided into five groups. Four groups
were given a single retrieval trial presentation of the tone
in the absence of a footshock. Extinction training then
began either 10 min, 1 h, 6 h, or 24 h later. The fifth group
was exposed to the context but did not receive memory
retrieval. Twenty-four hours later, all groups were tested
to see if they would show between-session extinction and
then they were tested once again, 1 month later. Twenty-
four hours after extinction all groups had low levels of
freezing. However, 1 month later, the groups given
extinction training 10 min or 1 h after recall showed no
spontaneous recovery, whereas the groups extinguished
6 or 24 h later did. Very similar results were seen when
relapse of extinction was measured with renewal or rein-
statement. Hence, just like extinction given shortly after
fear conditioning seems to block consolidation extinction
given shortly after recall seems to block reconsolidation.
Importantly, this work was extended in humans and
extinction given shortly after recall blocked spontaneous
recovery 1 year later!
21 These are exciting results and
clearly indicate that the timing of extinction either after
original learning or after memory recall can have pro-
found effects on the durability of extinction. It remains
unclear, however, as to why a 10-min interval between
the first extinction trial (ie, a memory retrieval trial is
identical to the first trial of extinction training) produces
such a different effect than the usual intertrial interval
during normal extinction training.
Role of NMDA receptors in extinction 
of conditioned fear in rodents
Like fear acquisition,
22 fear extinction depends on
NMDA receptors within the basolateral amygdala. Thus,
intra-amygdala infusions of a compound that blocks
NMDA receptors prior to extinction training dose-
dependently blocked retention of extinction of fear-
potentiated startle measured 1 day after extinction train-
ing.
23 This impairment could not be attributed to an
effect on NMDA receptors outside the amygdala, to
damage or destruction of the amygdala, or to an impair-
ment of sensory transmission during extinction training.
Later studies showed that systemic administration of
NMDA receptor antagonists prior to fear extinction
training lead to dose-dependent impairments of both
within-session extinction and extinction retention.
24-28
Systemic NMDA receptor antagonists also impair
extinction retention or reinstatement when administered
immediately after extinction training,
29-32 indicating that
NMDA receptors are involved in consolidation as well
as encoding of extinction memory. A similar blockade of
extinction of contextual fear conditioning, and inhibitory
avoidance conditioning has been reported with both sys-
temic and localized administration of various NMDA
receptor antagonists,
33,34 and additional studies have con-
firmed that these effects cannot be explained by state
dependency.
24,35
Different effects of NMDA blockade in the amygdala
and medial prefrontal cortex on extinction
The medial prefrontal cortex (mPFC) sends dense pro-
jections to the amygdala that terminate, in part, on
inhibitory interneurons.
36-40 Hence, mPFC is in a posi-
tion to inhibit the amygdala, a possible extinction
mechanism,
41 at least under some circumstances.
42,43
Electrolytic lesions
44 or localized inactivation
45 of the
infralimbic region of mPFC impair extinction retention
while having little to no effect on acquisition or within-
session extinction, suggesting a role for this region
466
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specifically in consolidation and/or expression of
extinction memory (see also ref 46). Single units within
infralimbic cortex fire selectively to presentations of a
previously fear-conditioned cue during an extinction
retention test 24 h after extinction training but not dur-
ing the extinction training session itself.
47 When infral-
imbic cortex microstimulation was paired with presen-
tations of a previously fear conditioned cue in
nonextinguished animals, freezing to those cues was
attenuated, and this effect was also seen the next day
when no stimulation was given.
47,48 Collectively, these
findings indicate that mPFC plays a significant role in
many cases in extinction memory consolidation and
expression, likely via its interactions with the amygdala.
NMDA receptors within amygdala seem to be involved
in the initiation of extinction, whereas in infralimbic cor-
tex, they seem to be involved in consolidation of extinc-
tion. Microinfusions of NMDA receptor antagonists into
basolateral nucleus of the amygdala prior to fear extinc-
tion training impair both within-session extinction and
extinction retention.
16,23,30,31,33 However, local infusions of
NMDA 2A, 2B antagonists into basolateral amygdala
block the expression of several fear-related conditioned
responses, including freezing, suggesting these drugs
could artifactually block extinction retention by inter-
fering with synaptic transmission. However, infusion of
ifenprodil, a drug that blocks a subtype of the NMDA
receptor but does not block expression of fear condi-
tioned responses, still blocked extinction retention.
28,30,31
Immediate post-extinction training infusions into the
amygdala of ifenprodil have no effect on subsequent
extinction retention when extinction of fear is mea-
sured.
27,30This suggests that NMDA receptor-dependent
synaptic plasticity within amygdala is involved in encod-
ing extinction of fear, but that the subtype of the NMDA
receptor where ifenprodil acts in the amygdala is not
required for consolidation of extinction, at least for con-
ditioned fear. 
In contrast, pre-extinction training infusions of NMDA
receptor antagonists into mPFC have no effect on
within-session extinction but generally impair later
extinction retention
29,31,49; (but see ref 27). Immediate
postextinction infusions of NMDA antagonists into the
infralimbic cortex do block extinction retention consis-
tently,
27,29-31 providing strong evidence that NMDA
receptor-dependent synaptic plasticity within this corti-
cal area is involved primarily in consolidation of extinc-
tion memory. 
NMDA receptors do not seem to be involved the 
second time extinction is given
Perhaps surprisingly, when the experimental protocol
involves fear acquisition and extinction followed by
reacquisition and re-extinction of the same cue, systemic
administration of the NMDA receptor antagonist MK-
801 prior to re-extinction training does not impair sub-
sequent extinction retention. However, it does block re-
extinction when the extinction retention test occurs in a
context different from that of initial acquisition and ini-
tial extinction,
50 suggesting that NMDA receptor activa-
tion is required when extinction events are relatively
novel but not when they are relatively familiar.
50 On the
other hand, novelty does not seem to matter for fear
conditioning itself because disruption of the NMDA
receptor blocks fear acquisition in both a novel and a
familiar context.
33,49
Effects of localized infusions of NMDA receptor antag-
onists prior to second extinction are more complex and
are reviewed elsewhere (see ref 51).
Role of D-cycloserine in 
fear extinction
Because blockade of the NMDA receptor impairs
extinction, we wondered whether enhancing the func-
tioning of that receptor would enhance extinction. To
test this we administered a compound called D-cycloser-
ine (DCS) either systemically or directly into the rats’
amygdala prior to extinction training and then tested
retention of extinction the next day.
52 DCS does not bind
to the NMDA receptor itself, but to another receptor on
the NMDA protein called the glycine regulatory site.
Activation of this site improves the ability of the NMDA
receptor protein to flux calcium which initiates a variety
of intracellular events that are critical for extinction. As
predicted, when DCS was given in combination with
repeated exposure to the feared stimulus without a
shock, extinction retention was enhanced, when testing
took place after DCS had worn off. This did not occur in
control rats that received the drug alone, without extinc-
tion training. Based on these results, we concluded that
the positive effects of the DCS were specifically con-
nected with extinction and did not result from a general
dampening of fear expression. 
These effects have now been replicated in a large num-
ber of studies. 
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Systemic administration of DCS either before
52-61 or
after
54 extinction training facilitates extinction. Local
infusion of DCS into the basolateral nucleus of the
amygdala prior to
52,62 or after
54 fear extinction training
mimics the effects of systemic administration. Chang and
Maren
63 recently showed that although DCS infusions
directly into infralimbic cortex did not facilitate extinc-
tion, these infusions did facilitate the subsequent re-
extinction of fear when animals were trained in a drug-
free state.
63
DCS may normalize impaired extinction
There is a growing body of evidence to suggest that DCS
reverses fear extinction deficits caused by a variety of
factors including stress,
64-66 alcohol withdrawal,
67 REM
sleep deprivation,
68 genetically modified mice that have
a polymorphism in their BDNF gene,
69 or even adoles-
cent rats in which the medial prefrontal cortex has not
yet developed fully.
70 Perhaps consistent with these
stress-related effects, DCS interacts with stress hor-
mones: DCS blocks the extinction-impairing effect of
the corticosteroid synthesis inhibitor metyrapone and
enhances the extinction-facilitating effects of the syn-
thetic glucocorticoid dexamethasone.
71 Judo et al
72
showed that changes in prefrontal synaptic efficacy dur-
ing extinction training did not occur in adult rats
exposed to early postnatal stress, and these synaptic
changes and resulting deficits in extinction were restored
by DCS. These observations may also be consistent with
findings in clinical studies described below, that DCS
facilitates exposure therapy in clinical, but not subclini-
cal, populations, and that different types of mechanisms
could be involved in the two groups of subjects.
73
DCS facilitates psychotherapy
Many forms of psychotherapy depend in part on
extinction of fear. Patients with fear of snakes avoid
snakes and do not allow themselves to extinguish this
fear. However, repeated exposure to pictures of snakes,
a snake in a jar, or even a live snake are extremely
effective in eliminating such simple phobias and are
widely used. Panic patients afraid they will have a panic
attack driving over a high bridge are taken back to the
bridge to show them that they will not always have a
panic attack there. Patients with a contamination pho-
bia who are forced to touch the bottom of a toilet seat,
but not allowed to wash their hands, learn not only they
do not die but they don’t even get sick, identical to an
extinction trial. Exposure to scenes of combat in peo-
ple with post-traumatic stress disorder (PTSD) in the
presence of a supportive therapist often leads to sub-
stantial improvement, and cognitive behavioral therapy
has been found to be helpful in many PTSD patients.
In all these cases of exposure-based psychotherapy
extinction is the fundamental mechanism that is oper-
ating.
The finding that DCS can facilitate fear extinction in ani-
mals
52 and that fear extinction was so central to many
types of psychotherapy suggested that DCS might also
be effective in facilitating exposure therapy for fear and
anxiety disorders in people. DCS had been FDA-
approved for some time as an antibiotic treatment for
tuberculosis at high doses. Although this effect had noth-
ing to do with its ability to facilitate extinction it allowed
us to test whether it would facilitate exposure-based psy-
chotherapy right away.
74
In this study, the ability of DCS to enhance exposure
therapy for acrophobia, or fear of heights, using virtual
reality exposure therapy, was examined. Previous work
had shown improvements on acrophobia outcome mea-
sures after seven or eight weekly virtual reality therapy
sessions.
75 Participants in the DCS study underwent a
suboptimal amount of virtual reality therapy for acro-
phobia (only two virtual reality sessions) and were
instructed to take a single dose of study medication
before each session. So DCS was only taken twice: prior
to each of the two sessions that were separated by aver-
age of 12 days. Similar to the rats in the preclinical work,
participants receiving DCS exhibited significantly more
improvement than did participants receiving placebo,
measured either 1 week or 3 months later, long after the
drug was out of the body (Figure 1A).
74 At the 1-week
follow-up, DCS-treated patients exhibited less subjec-
tive fear and fewer skin conductance fluctuations in the
virtual reality environment. 
Most importantly, outside of the virtual reality environ-
ment patients reported a decrease in overall acrophobia
symptoms, increased self-reports of exposure to heights
in the “real world,” and higher self-ratings of improve-
ment. These later results are very important because
they indicate that extinction of fear is not always con-
text-specific, as seen so often in animal studies. The rea-
son for this appears to be that humans begin to feel safe
in situations they previously avoided, once they have
PAGES_12_AG_1005_BA.qxd:DCNS#51  1/12/11  14:54  Page 468some successful psychotherapy and avoid these situa-
tions less often. People with fear of elevators do not
want to continue to walk up 20 flights of stairs once they
learn the elevator will not harm them. In contrast, rats
have no opportunity to continue to extinguish because
they are put back in their home cage with no further
exposure to the fearful conditioned stimulus. So, the sev-
eral measures of relapse from extinction may be over-
estimated in rodent studies.
Other groups found that DCS enhanced exposure ther-
apy for social anxiety disorder—Figure 1B,
76,77 obsessive-
compulsive disorder—Figure 1C,
78,79 and panic disor-
der—Figure 1D,
80 indicating that the DCS effect is a
relatively general one. The failure of another study to see
on effect in OCD
81 may have resulted from giving DCS
4 hours prior to exposure therapy, which may have been
too early. There has been one report of a failure of DCS
to facilitate exposure therapy for subclinical spider pho-
469
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Figure 1. Facilitation of exposure-based psychotherapy by D-cycloserine (DCS) in patients with fear of heights (A); social phobia (B); obsessive-com-
pulsive disorder (C), or panic disorder (D). 
Reproduced from ref 74: Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic
individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004;61:1136-1144. Copyright © American Medical Association 2004; ref 77: Hofmann SG,
Meuret AE, Smits JA, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006;63:298-304. Copyright
© American Medical Association 2006; ref 79: Wilhelm S, Buhlmann U, Tolin DF, et al. Augmentation of behavior therapy with D-cycloserine for obsessive-
compulsive disorder. Am J Psychiatry. 2008;165:335-341; quiz 409. Copyright © Hanover 2008; ref 80: Otto MW, Tolin DF, Simon NM, et al. Efficacy of d-
cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry. 2010;67:365-370. Copyright © Elsevier 2010
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bia,
82 and failures of DCS to facilitate extinction of
Pavlovian conditioned fear in a laboratory situation in
humans.
73,82 However, these negative effects may indicate
that DCS is useful only in people with clinically signifi-
cant, maladaptive fear—consistent, perhaps, with the
preclinical data suggesting that DCS is particularly effec-
tive in stressed animals (described above).
A note of caution
DCS may not work on re-extinction
It should be recalled that NMDA antagonists block
extinction the first time extinction training is carried out
but not when rats are retrained and then extinguished
again.
50The same is true for D-cycloserine.
83
DCS and serotonin reuptake inhibitors
DCS also failed to facilitate extinction in rats with prior
administration of a serotonin reuptake inhibitor
(imipramine).
84 However, because it is likely that many
patients in the positive trials of DCS in anxiety disor-
ders were taking serotonin reuptake inhibitors, it is hard
to know how important this variable is because the
database is just not large enough to allow an adequate
evaluation of this variable. In our own study of fear of
heights we could find no relationship. 
DCS shows tolerance
DCS also failed to facilitate extinction in rats given prior
daily injections of DCS,
85 consistent with several pre-
clinical studies showing tolerance with repeated DCS
treatment.
85 Hence, we suggest spacing DCS treatments
by at least a week. 
DCS should not be given too far in advance of psy-
chotherapy
As mentioned above, DCS is known to facilitate consol-
idation of fear extinction so it is important not to give it
too early prior to psychotherapy. In fact, post-extinction
training is used routinely in rodent studies and this may
be especially effective clinically. For example, if a patient
had a bad session of psychotherapy it might not be use-
ful to use DCS. But, if they have a good session then the
therapist could give DCS right after therapy, which
would more likely cover the consolidation period and
improve compliance.
86 In fact, we have preliminary data
in rats that giving DCS prior to sleep, when many types
of memory consolidate, may be especially effective
(Davis, Bowser, McDevitt, and Walker, in revision). 
DCS is very unstable in humid conditions and in solution
It is very important to keep it dry during compounding
into lower doses from Seromycin as well as in storage.
87
Will DCS make patients worse? 
A question that is often asked is why, if DCS is a cogni-
tive enhancer, does it not stamp in the bad memories
brought up during psychotherapy and make patients
worse? DCS has been shown to facilitate retention of
inhibitory avoidance and spatial learning in rats,
88 stim-
ulus attributes in inhibitory avoidance in rats,
89 inhibitory
avoidance in chicks
90 or mice,
91,92 thirst-motivated maze
learning in mice,
93 object location in mice,
94 taste aver-
sion in rats,
95,96 delayed nonmatching-to-sample in rhesus
monkeys,
97 and acquisition of eyeblink conditioning in
rabbits when trace conditioning was used.
98 It also
improves memory due to aging in mice,
91 spatial mem-
ory in rats,
99 and eyeblink conditioning in rabbits.
100 In
rats, DCS reverses scopolamine-induced deficits in: the
T-maze and water maze,
101 working memory,
102 or
inhibitory avoidance,
103 or reduces deficits following
brain injury
104 or hippocampal lesions,
105 or deficits in
inhibitory avoidance in mice caused by β 25-35-
amyloid peptides
106 or convulsant drugs.
107
Because most, if not all, these tasks depend on the hip-
pocampus, one might expect that DCS would facilitate
hippocampally dependent declarative memory in
humans. However, the literature is very inconsistent in
this area. Otto et al
108 found no effect of DCS in improv-
ing verbal or nonverbal learning given at weekly sessions
nor did D'Souza et al
109 on several tests of verbal learn-
ing and it had no effect on a procedural task (finger tap-
ping). On the other hand, improvement of procedural
learning (sequential finger tapping) but not of declara-
tive (word-pair) learning by DCS was found.
110 DCS
accelerated rate of learning on item-category associa-
tions, but had no beneficial effect in the object-location
association task, both declarative memory tasks.
111There
was improvement on one cognitive task (delayed the-
matic recall on the logical memory test) in schizophrenic
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patients.
112There was one report showing enhanced fear
conditioning with DCS in humans,
86 but the study design
was so complex that it is hard to know what to conclude
from this study, especially because there appear to be no
positive studies of DCS on classical fear conditioning in
humans. Finally, no reports were found of patients get-
ting worse on or after DCS in the six positive studies
that have been published with cognitive behavioral ther-
apy. Hence, despite the ability of DCS to facilitate learn-
ing in animal studies, for reasons that are not clear, this
has not been found universally in humans, even though
DCS generally has facilitated fear extinction in clinical
populations. Possible reasons for this are discussed else-
where.
113
Conclusion
Because excessive fear and anxiety occur in so many
psychiatric disorders, research continues to investigate
how the brain normally inhibits or suppresses these
emotions.  Exposure-based cognitive behavioral therapy
(CBT), in which patients are repeatedly exposed to anx-
iogenic situations in the absence of any aversive conse-
quences, has been quite successful in treating these dis-
orders. CBT is procedurally similar to fear extinction in
animals, in which a fearful stimulus also is exposed
repeatedly without aversive events.  Extinction does not
erase the original fear memory but instead actively
inhibits that memory.  It is dependent on a protein called
the NMDA receptor in brain areas such as the amygdala
and medial prefrontal cortex.  A medication called D-
cycloserine allows the NMDA receptor to work even
better and it also facilitates fear extinction, especially
when extinction is compromised following stress.
However, it does not work when given alone, but only in
combination with extinction training.  Six independent
clinical trials have shown that D-cycloserine facilitates
CBT in patients with phobia, obsessive-compulsive and
panic disorder, and several trials are underway to tests
its effects in PTSD.  Continued analysis of normal and
abnormal fear extinction in animals will almost surely
lead to other medications to facilitate CBT. ❏
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